Zacks Investment Research·1d ago
SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales DeclineSarepta's mixed Q3 results send shares down, as earnings miss and weaker Elevidys sales weigh on investor sentiment.
Sarepta's fundamentals are characterized by extreme quarterly volatility, with revenue swinging from $744.9M in 2025Q1 to $401.3M in 2026Q2 and gross margins collapsing to 10.0% in 2025Q4, yet the company has deleveraged from a D/E of 1.44 in 2024Q1 to 0.68 in 2026Q2.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $0.13+75.6% vs $0.07 | $381M+8.3% vs $352M |
Q3 2026 Aug 5, 2026 | -$0.05-123.0% vs $0.22 | $401M+9.5% vs $366M |
Q2 2026 May 6, 2026 | $3.16+223.8% vs $0.98 | $731M+54.1% vs $474M |
Q1 2026 Feb 25, 2026 | -$3.58-247.6% vs -$1.03 | $443M+19.8% vs $370M |
Sarepta's mixed Q3 results send shares down, as earnings miss and weaker Elevidys sales weigh on investor sentiment.
Sarepta Therapeutics NASDAQ: SRPT raised the low end of its 2026 product revenue forecast after reporting stable demand indicators for Duchenne muscular dystrophy gene therapy ELEVIDYS and continued strength in its exon-skipping drug franchise.
While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2026. “After my first 90 days at Sarepta, I believe the fundamental strengths that attracted me to the company remain firmly intact: a durable Duchenne franchise, a promising pipeline with the potential to deliver differentiated medicines, and the financial strength to invest in our highest-value opport.
Benchmark SRPT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Sarepta Therapeutics, Inc. (SRPT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $17.82 | $1.88B | 127.93 | 15.58% | 0.75% | 1.04% | — | |
| $56.03 | $10.83B | -567.68 | 12.87% | -0.52% | -0.31% | — | |
| $155.94 | $20.82B | 7.90 | 65.19% | 54.34% | 159.72% | — | |
| $15.43 | $1.52B | -3.01 | 20.13% | -71.78% | — | — | |
| $39.42 | $6.55B | -11.55 | 33.87% | -64.64% | -110.84% | — | |
| $300.88 | $8.87B | 41.21 | 33.94% | 47.91% | 17.02% | — |
Sarepta Therapeutics, Inc. (SRPT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Sarepta Therapeutics, Inc. (SRPT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jul 27, 2026·SEC
Jun 4, 2026·SEC
Get notified when SRPT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Sarepta Therapeutics, Inc. (SRPT) stock FAQ — growth, dividends, profitability & financials explained
Sarepta Therapeutics, Inc. (SRPT) reported $1.96B in revenue over the trailing twelve months. Revenue was $2.20B in fiscal year 2025. That is 2198137% more than the $0.1M of fiscal year 1996.
Sarepta Therapeutics, Inc. (SRPT) revenue fell by 18.9% over the trailing twelve months, compared with the twelve months before.
Yes. Sarepta Therapeutics, Inc. (SRPT) earned $14.8M in net income over the trailing twelve months (a 0.8% net margin).
Sarepta Therapeutics, Inc. (SRPT) had a return on equity (ROE) of 1.0% over the trailing twelve months. That is below the market's typical 10-15%.
Sarepta Therapeutics, Inc. (SRPT) had negative free cash flow of $31.6M over the trailing twelve months.
